Posted On: 10/13/2015 9:03:57 PM
Post# of 72440
Sieffert - 2 part Bioflash series in Boston Biz Journal on Paratek Rx and ABX.
IV to pill formulation. $50m. Yikes.
//
PART 1
"The rise of the superbug: Paratek’s two-decade struggle to develop an antibiotic"
http://www.bizjournals.com/boston/blog/biofla...ecade.html
PART 2
"How Paratek Pharmaceuticals hopes to succeed in antibiotics despite Tetraphase’s fail"
http://www.bizjournals.com/boston/blog/biofla...otics.html
EXCERPT
Paratek’s pill formulation of its drug may be superior to Tetraphase’s. Thanks to its past partnership with Novartis, which invested around $50 million making omadacycline from an intravenous medicine into a pill, Loh says Paratek’s pill is just as potent as its IV version, and less likely to cause nausea and vomiting which can lessen the amount of drug a patient gets. It also means it can be prescribed by doctors outside of hospitals, where some two-thirds of the total market for antibiotics lies.
IV to pill formulation. $50m. Yikes.
//
PART 1
"The rise of the superbug: Paratek’s two-decade struggle to develop an antibiotic"
http://www.bizjournals.com/boston/blog/biofla...ecade.html
PART 2
"How Paratek Pharmaceuticals hopes to succeed in antibiotics despite Tetraphase’s fail"
http://www.bizjournals.com/boston/blog/biofla...otics.html
EXCERPT
Paratek’s pill formulation of its drug may be superior to Tetraphase’s. Thanks to its past partnership with Novartis, which invested around $50 million making omadacycline from an intravenous medicine into a pill, Loh says Paratek’s pill is just as potent as its IV version, and less likely to cause nausea and vomiting which can lessen the amount of drug a patient gets. It also means it can be prescribed by doctors outside of hospitals, where some two-thirds of the total market for antibiotics lies.
(0)
(0)Scroll down for more posts ▼
